Results 131 to 140 of about 9,998 (163)

Unmasking the phospholipid-induced "hook effect" and its implications - increasing phospholipid can also lead to a longer clotting time in coagulation assays. [PDF]

J Thromb Thrombolysis
Ling L, Liu C, Huang X, Wang S, Yu Z, Zhou J.   +5 more
europepmc   +1 more source

Neutrophil extracellular traps and pyroptosis: a molecular nexus linking systemic autoimmune diseases to atherosclerosis. [PDF]

Front Immunol
Du Y, Zhang L, Cheng Y, Lu S, Ou R, Deng X.   +5 more
europepmc   +1 more source

Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases. [PDF]

Curr Issues Mol Biol
Kanno Y.
europepmc   +1 more source

Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths. [PDF]

Sci Rep
Matsuda M, Shimomura D, Suzuki T, Tabuchi Y, Kurono H, Nishi K, Arai N, Hoshiyama Y, Kamioka M, Moriyama M, Matsumoto T.   +10 more
europepmc   +1 more source

Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada. [PDF]

EJHaem
Blackman R, Chen LYC, Keating MM, Quinn J, Robinson S.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Recurrent Venous Thrombosis with a “Lupus” Coagulation Inhibitor in the Absence of Systemic Lupus

Australian and New Zealand Journal of Medicine, 1977
A young man presenting with recurrent deep venous thrombosis was found to have a lupus type coagulation inhibitor. He showed neither clinical nor serological evidence of systemic lupus. The value of the Russell viper venom coagulation time in the detection of the inhibitor is demonstrated.
A, Manoharan, L, Gibson, B, Rush, B J, Feery   +3 more
exaly   +3 more sources

Studies on Phospholipids in the Action of a Lupus Coagulation Inhibitor

Pathology, 1975
Plasma from a patient with early manifestations of disseminated lupus erythematosus, a prolonged partial thromboplastin time with kaolin, mildly prolonged prothrombin time, and a circulating inhibitor affecting the assay of several clotting factors was investigated.
H Kronenberg, Thomas Exner
exaly   +3 more sources

A Circulating Lupus-like Coagulation Inhibitor Induced by Chlorpromazine

Journal of Clinical Psychopharmacology, 1984
A variety of immune phenomena have been associated with chlorpromazine. One such factor, the lupus-like anticoagulant, while nonspecific, has been reported in 26 to 75% of chronic chlorpromazine recipients, although the exact incidence is unknown and requires further investigation.
G, Tollefson, K, Rodysill, M, Cusulos
exaly   +3 more sources

Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus

British Journal of Haematology, 1996
An acquired IgG inhibitor to factor XIII was identified in a 30‐year‐old Vietnamese woman with systemic lupus erythematosus. The IgG fraction was isolated from plasma by chromatography on an agarose gel column and by protein G adsorption. The anti‐factor XIII activity, identified within the IgG fraction, inhibited factor XIII from both normal plasma ...
Man-Chiu Poon, Ferhaan Ahmad, S Solymoss   +2 more
exaly   +3 more sources

New method to differentiate between lupus anticoagulants, progressive coagulation inhibitors and coagulation factor deficiencies in the mixing tests

International Journal of Laboratory Hematology
AbstractIntroductionMixing tests in activated partial thromboplastin time (APTT) are used for the differentiation between lupus anticoagulants (LA), coagulation inhibitors, and factor deficient samples with APTT prolongation. However, the indexes for the differentiation have not been established.
Shimomura Daiki, Osamu Kumano
exaly   +3 more sources